GENX — Genix Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- CA$1.22m
- CA$2.47m
Annual cashflow statement for Genix Pharmaceuticals, fiscal year end - October 31st, CAD millions except per share, conversion factor applied.
2021 October 31st | 2022 October 31st | 2023 October 31st | 2024 October 31st | 2025 October 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.65 | -1.07 | -4.4 | -0.073 | -0.335 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.811 | 0.296 | 3.57 | -0.145 | 0.177 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.124 | -0.006 | 0.056 | 0.03 | 0.032 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -0.428 | -0.22 | -0.221 | -0.187 | -0.124 |
| Capital Expenditures | 0 | -0.003 | 0 | — | — |
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | 0 | -0.003 | 0 | — | — |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.129 | 0.093 | 0.223 | 0.187 | 0.156 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.558 | -0.13 | 0.002 | -0 | 0.032 |